Savara shares are crushed as PhI­II tri­al flunks pri­ma­ry, key sec­on­daries — but they can’t stop be­liev­ing

7 years ago
R&D

As an­oth­er an­tibi­otics biotech sinks in­to a cri­sis, warn­ings of a sec­tor ‘col­lapse’

7 years ago
R&D

Fol­low­ing CAR-T pi­o­neer­s' foot­steps, Tes­sa launch­es Chi­na JV in $120M deal

7 years ago
Financing
China

An in­censed Cat­a­lyst Phar­ma sues the FDA, ac­cus­ing agency of bow­ing to po­lit­i­cal pres­sure and break­ing fed­er­al law

7 years ago
Pharma
FDA+

Tech con­glom­er­ate buys Me­di­da­ta for $5.7B; Alexan­dria teams up with Co­lum­bia for sec­ond Launch­Labs; So­bi all in on ...

7 years ago
News Briefing

Or­biMed-backed Pre­lude Ther­a­peu­tics rais­es $60M to tack­le re­sis­tance to can­cer treat­ments

7 years ago
Financing
Startups

Plagued by de­lays, As­traZeneca HQ costs soar to £750M as it edges to­ward 2020 com­ple­tion

7 years ago
Pharma

Fresh analy­sis spot­lights car­dio ben­e­fit of J&J's In­vokana in di­a­betes pa­tients with­out his­to­ry of CV dis­ease

7 years ago
Pharma

Sil­i­con Val­ley's most an­tic­i­pat­ed slide deck just dropped. What does it mean for bio­phar­ma's dig­i­tal teams?

7 years ago
Bioregnum
Pharma

Bain’s biotech team has cre­at­ed a $1B-plus fund — with an eye to more Big Phar­ma spin­outs

7 years ago
Financing

Syn­log­ic, Gink­go ex­pand mi­cro­bial dis­cov­ery pact, throw­ing $80M in­vest­ment in­to the mix

7 years ago
R&D

ADC Ther­a­peu­tics beefs up mon­ster $200M round with fresh $76M haul

7 years ago
Financing

Roche cat­a­pults Thomas Schi­neck­er to chief of di­ag­nos­tics unit

7 years ago
People

Nas­daq delists In­sys af­ter bank­rupt­cy fil­ing; Chi­na's Zai Lab li­cens­es sol­id tu­mor drug from De­ci­phera

7 years ago
News Briefing

Search­ing for the next block­buster to fol­low Darza­lex, J&J finds a $150M an­ti-CD38 drug from part­ner Gen­mab

7 years ago
R&D

Mer­ck grows Keytru­da in­di­ca­tions with head and neck can­cer ap­proval

7 years ago
Pharma

NASH con­tender CymaBay runs in­to trou­ble as mid-stage da­ta dis­ap­point

7 years ago
R&D

Russ­ian sci­en­tist plans to one-up Jiankui He in cre­at­ing his own CRISPR ba­bies — Na­ture

7 years ago
Discovery

With a sub­stan­tial dis­count to Cat­a­lyst's Fir­dapse, is Ja­cobus poised to win physi­cian, pay­er sup­port for off-la­bel ...

7 years ago
Pharma

In a boost to Rit­ux­an fran­chise, Roche nabs quick ap­proval for po­latuzum­ab ve­dotin

7 years ago
Pharma

FDA sends No­vaVax back to the clin­ic; Stoke Ther­a­peu­tics sets terms for up­sized $101M IPO

7 years ago
News Briefing

Lil­ly's Trulic­i­ty CV out­comes da­ta un­der­whelm amid block­buster di­a­betes ri­val­ry with No­vo

7 years ago
Pharma

Bat­tered by le­gal ex­pens­es, opi­oid drug­mak­er In­sys files for bank­rupt­cy days af­ter $225M deal to set­tle gov­ern­ment ...

7 years ago

Stick­ing to hottest trends in bio­phar­ma, On­colo­gie gath­ers $80M for next leg of trans-Pa­cif­ic clin­i­cal jour­ney

7 years ago
Startups
First page Previous page 941942943944945946947 Next page Last page
A service from the Financial Times